Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its Lingo device - and ...

In June 2024, Abbott received a pair of clearances for its Libre Rio and Lingo CGM systems, both the company’s first to become available without a prescription. Based on its FreeStyle Libre ...

Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

Eversense 365, the world’s first 365-day CGM system, is the only CGM offering a year-long wear time. Market-leading, ...

A CGM helps me run marathons and do epic bike rides better than ever.

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, nutrition and ...

Abbott's revenue for the fourth quarter of 2024 ... in recent years as it is the first continuous glucose monitoring [CGM] system that is available without the need to see a doctor for a prescription.

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma.Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive powerlift ...

Libre Drives Diabetes Care: Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.